Immutep (IMMP) Other Accumulated Expenses (2016 - 2025)
Immutep (IMMP) posted Other Accumulated Expenses of $260764.9 for Q4 2025, down 8.9% on a QoQ basis from $286241.0 in Q2 2025, and down 46.39% year-over-year from $486442.3 in Q4 2024.
Immutep (IMMP) Other Accumulated Expenses (2016 - 2025) Analysis & Trends
Immutep's Other Accumulated Expenses history runs 3 years deep, the most recent figure standing at $260764.9 for Q4 2025.
- Quarterly Other Accumulated Expenses fell 46.39% year-over-year to $260764.9 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $260764.9 (down 46.39% YoY) and the FY2025 annual result came in at $286241.0, up 1.31% from the prior year.
- Other Accumulated Expenses was $260764.9 for Q4 2025 at Immutep, down from $286241.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $486442.3 in Q4 2024 and bottomed at $260764.9 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Immutep | 562.38 Mn | 562.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 260,764.88 |
| Jun 30, 2025 | 286,240.98 |
| Dec 31, 2024 | 486,442.35 |
| Jun 30, 2024 | 282,529.07 |
| Mar 31, 2016 | -986,885.62 |